Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)

Trial Profile

A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms SELECTION
  • Sponsors Biogen Idec
  • Most Recent Events

    • 28 Apr 2017 Results examining degree of return of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) following discontinuation of treatment with daclizumab HYP (daclizumab) in SELECT/SELECTION Studies presented at the 69th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results (pooled analysis of SELECT and SELECTION studies, n = 73) assessing effects of daclizumab HYP 150mg on total and differential lymphocyte populations presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 20 Apr 2016 A post-hoc analysis of results from SELECT and SELECTION trials presented at the 68th Annual Meeting of American Academy of Neurology (AAN)2016, according to a Biogen media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top